Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 7/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814704 | 0.92 | SOS1 (0.33) | LIPE | |
| SCHEMBL14815313 | 0.91 | LIPE (0.34) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14814929 | 0.91 | LIPE (0.34) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14815224 | 0.91 | LIPE (0.34) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14815210 | 0.85 | LIPE (0.41) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14815447 | 0.84 | DPP4 (0.36) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14815291 | 0.84 | LIPE (0.35) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14815220 | 0.84 | LIPE (0.35) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14815398 | 0.83 | TEAD1 (0.35) | LIPEDPP4DPP7DPP8PSEN1 | |
| SCHEMBL14814867 | 0.83 | SOS1 (0.34) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | LIPE 4720/4885DPP4 578/4885DPP7 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.